SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?

J Clin Invest. 2021 Dec 1;131(23):e156309. doi: 10.1172/JCI156309.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Benzhydryl Compounds / pharmacology
  • Clinical Trials, Phase III as Topic
  • Female
  • Glucosides / pharmacology
  • Heart Failure / drug therapy*
  • Hospitalization
  • Humans
  • Male
  • Metabolic Diseases / drug therapy*
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Sodium-Glucose Transporter 2 / chemistry*
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology*
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Function, Left / drug effects*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin